Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.35 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: zotiraciclib, azd-5438, seliciclib +11 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 24 Parkinson's papers of 9,700 | 0.58 |
| pathways Reactome | 27 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 0881
Sealed predictions
- CDK2 in dopamine neurons, braak-0.29 (p 0.457) → +0.17 (p 0.671)receipt 0889
Swarm cases
receipt 0889: CDK2 in dopamine neurons, braak
- power
- full sample -0.11 (p 0.671, n 18), 95% CI -0.55 to +0.38. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.17 (p 0.493, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.509, n 18). could be the mix.
- skeptic
- leave-one-out range -0.20 to +0.01, sign flips 1; without severely affected donors -0.11 (p 0.671, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CDK2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts